GlassScriptPhysician profile
Raymond C Sultan
NPI 1033364351
$4,680.93
in general payments reported to CMS, 2019-2025
35 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $221 · 2021: $596 · 2022: $537 · 2023: $1,040 · 2024: $641 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $802.83 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $547.59 | 2023-2025 | Orgovyx, Gemtesa |
| Procept Biorobotics Corporation | $392.83 | 2019-2025 | Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $389.95 | 2019-2025 | Adstiladrin |
| Urogen Pharma, INC. | $245.75 | 2021-2025 | Jelmyto |
| Antares Pharma, INC. | $234.44 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $231.55 | 2019-2025 | |
| Myovant Sciences INC. | $174.39 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $166.65 | 2021-2024 | Prolaris |
| Neotract INC. | $162.80 | 2019 | |
| Coloplast Corp | $147.37 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $144.41 | 2019-2024 | Xiaflex, Aveed |
| Astellas Pharma US INC | $128.13 | 2019-2024 | Xtandi |
| Tolmar, INC. | $106.68 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $102.69 | 2023-2025 | Pylarify |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edap Technomed INC | $100.00 | 2023 | |
| Acerus Pharmaceuticals Corporation | $92.05 | 2021-2022 | |
| Srs Medical Systems, INC. | $61.92 | 2024-2025 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Tolmar Pharmaceuticals, INC. | $57.47 | 2019-2021 | |
| Halozyme INC | $47.18 | 2023 | |
| Laborie Medical Technologies Corp. | $34.98 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Cycle Pharmaceuticals INC | $28.58 | 2024 | Tiopronin |
| Abc Home Medical Supply, INC. | $28.13 | 2022 | |
| Urovant Sciences INC | $27.11 | 2022 | |
| Blue Earth Diagnostics | $26.68 | 2022 | |
| Boston Scientific Corporation | $26.43 | 2019 | |
| Immunitybio, INC. | $25.35 | 2025 | |
| Mannkind Corporation | $24.97 | 2023 | Afrezza |
| Abbvie INC. | $21.24 | 2023 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2020 | |
| Axonics, INC. | $18.97 | 2023 | Bulkamid |
| Pacira Pharmaceuticals Incorporated | $16.42 | 2022 | |
| Teleflex LLC | $15.79 | 2023 | Urolift |
| Sagent Pharmaceuticals | $14.98 | 2020 | |
| Endo USA, INC. | $14.25 | 2024 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Sultan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.